Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2019 16:01 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Reports First Quarter 2019 Financial Results and Recent Corporate Progress

Completed underwritten public offering of common stock that raised $46.2 million in net proceeds Received FDA Breakthrough Therapy designation for PB2452 Results from Phase 1 clinical trial of...
May 02, 2019 08:00 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio To Report First Quarter 2019 Financial Results and Recent Corporate Progress on May 9, 2019

MALVERN, Pa. and SAN DIEGO, May 02, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
April 16, 2019 16:01 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

MALVERN, Pa. and SAN DIEGO, April 16, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
April 11, 2019 21:19 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Announces Pricing of Public Offering of Common Stock

MALVERN, Pa., and SAN DIEGO, April 11, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
April 09, 2019 16:45 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Announces Proposed Public Offering of Common Stock

MALVERN, Pa. and SAN DIEGO, April 09, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
April 09, 2019 08:00 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Announces Global License of PB1023 for the Treatment of Sarcopenia-Related Diseases to ImmunoForge

MALVERN, Pa. and SAN DIEGO, April 09, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
April 08, 2019 16:01 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Receives FDA Breakthrough Therapy Designation for PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor

MALVERN, Pa. and SAN DIEGO, April 08, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
March 26, 2019 16:01 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Reports Fourth Quarter and Full-Year 2018 Financial and Business Results

Results from Phase 1 clinical trial of PB2452 published in the New England Journal of Medicine and presented at the American College of Cardiology’s Annual Scientific Session Initiated Phase 2b trial...
March 25, 2019 16:30 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Announces Term Loan of up to $15 Million

Entered into term loan facility with Silicon Valley Bank and WestRiver Innovation Lending Fund to borrow up to $15 million Funds will be used to advance clinical development of PB2452, a reversal...
March 19, 2019 08:00 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio To Report Fourth Quarter and Full-Year 2018 Financial and Business Results on March 26, 2019

MALVERN, Pa. and SAN DIEGO, March 19, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...